ישראל - עברית - Ministry of Health

bioavenir ltd, israel - finasteride - טבליות מצופות פילם - finasteride 1 mg - finasteride

ישראל - עברית - Ministry of Health

novartis israel ltd - secukinumab - תמיסה להזרקה - secukinumab 150 mg/ml - secukinumab

ישראל - עברית - Ministry of Health

inovamed pharma ltd, israel - dutasteride; tamsulosin hydrochloride - קפסולה קשיחה - dutasteride 0.5 mg; tamsulosin hydrochloride 0.4 mg - tamsulosin

ישראל - עברית - Ministry of Health

unipharm trading ltd, israel - dutasteride; tamsulosin hydrochloride - קפסולה קשיחה - tamsulosin hydrochloride 0.4 mg; dutasteride 0.5 mg - tamsulosin and dutasteride

ישראל - עברית - Ministry of Health

sanofi israel ltd - amiodarone hydrochloride - תמיסה להזרקה - amiodarone hydrochloride 50 mg / 1 ml - amiodarone - amiodarone - corronary insufficiency, arrhythmias resistant to other treatments, wolf parkinson white syndrome.

ישראל - עברית - Ministry of Health

glaxo smith kline (israel) ltd - dutasteride; tamsulosin hydrochloride - קפסולות - dutasteride 0.5 mg; tamsulosin hydrochloride 0.4 mg - tamsulosin - tamsulosin - treatment of moderate to severe symptoms of benign prostatic hyperplasia (bph). reduction in the risk of acute urinary retention (aur) and surgery in patients with moderate to severe symptoms of bph.

ישראל - עברית - Ministry of Health

glaxo smith kline (israel) ltd - dutasteride - קפסולות רכות - dutasteride 0.5 mg - dutasteride - dutasteride - avodart monotherapy is indicated for : - treatment of moderate to severe symptoms of benign prostatic hyperplasia (bph).- prevention of acute urinary retention and surgery in patients with bph.avodart in combination with the alpha-blocker tamsulosin is indicated for : - treatment of moderate to severe symptoms of benign prostatic hyperplasia (bph).

ישראל - עברית - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - exemestane - טבליות מצופות - exemestane 25 mg - exemestane - exemestane - aromasin is indicated for the treatment of advanced breast cancer (abc) in women with natural or induced postmenopausal status whose disease has progressed following anti-oestrogen therapy alone. aromasin is also indicated for the treatment of postmenopausal women with abc whose disease has progressed following multiple hormonal therapies. aromasin is indicated for the adjuvant treatment of postmenopausal women with oestrogen receptor positive invasive early breas cancer following 2-3 years of initial adjuvant tamoxifen therapy.

ישראל - עברית - Ministry of Health

bristol, myers squibb (israel) limited, israel - abatacept - אבקה להכנת תמיסה מרוכזת לעירוי - abatacept 250 mg - abatacept - abatacept - orencia in combination with methotrexate is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who responded inadequately to previous therapy with one or more disease modifying anti rheumatic drugs (dmards) including methotrexate (mtx) or a tnf-alpha inhibitor.a reduction in the progression of joint damage and improvement of physical function have been demonstrated during combination treatment with abatacept and methotrexate.polyarticular juvenile idiopathic arthritis:orencia in combination with methotrexate is indicated for the treatment of moderate to severe active polyarticular juvenile idiopathic arthritis (jia) in paediatric patients 6 years of age and older who have had an insufficient response to other dmards including at least one tnf inhibitor. orencia has not been studied in children under 6 years old.

ישראל - עברית - Ministry of Health

bristol, myers squibb (israel) limited, israel - abatacept - תמיסה להזרקה - abatacept 125 mg/ml - abatacept - abatacept - orencia is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis. orencia may be used as monotherapy or concomitantly with disease-modifying antirheumatic drugs (dmards) other than tumor necrosis factor (tnf) antagonists.